ИММУНОЛОГИЧЕСКИЕ АСПЕКТЫ ЭССЕНЦИАЛЬНОЙ ГИПЕРТЕНЗИИ
https://doi.org/10.15789/1563-0625-2019-3-407-418
Аннотация
Согласно современным представлениям об этиопатогенезе эссенциальной гипертензии, важная роль в ее развитии принадлежит клеткам иммунной системы. Медиаторы, продуцируемые иммунокомпетентными клетками, принимают участие в возникновении и поддержании состояния хронического системного воспаления и способствуют развитию сосудистого ремоделирования, являющегося важным звеном патогенеза заболевания и поражения органов-мишеней. Иммунные механизмы, лежащие в основе повышения артериального давления, включают в себя активацию клеток врожденного и приобретенного иммунитета. Нарушение целостности эндотелия сосудов, запускающее каскад воспалительных реакций, вызывает миграцию в очаг повреждения клеток иммунной системы, привлеченных хемокинами и молекулами адгезии. Инфильтрация макрофагами периваскулярной ткани способствует нарушению вазодилатации и повреждению органов-мишеней благодаря выработке активных форм кислорода. Ангиотензин II вызывает также инфильтацию периваскулярной жировой ткани и адвентиции Т-лимфоцитами и повышенную выработку фактора некроза опухолей альфа и интерферона гамма. Кроме того, Т-лимфоциты экспрессируют минералокортикоидный рецептор, участвующий в развитии системной гипертензии. Важная роль в прогрессировании гипертензии принадлежит интерлейкину-17, участвующему в развитии повышенного артериального давления и ремоделирования сосудов. В обзоре также представлены данные о влиянии кишечной микрофлоры на регуляцию артериального давления и развитие гипертензии.
Ключевые слова
Об авторе
Я. Р. Тимашева
Институт биохимии и генетики Уфимского федерального исследовательского центра Российской академии наук; ФГБОУ ВО «Башкирский государственный медицинский университет»
Россия
Россия
к.м.н., научный сотрудник лаборатории физиологической генетики, (450054, Республика Башкортостан, г. Уфа, пр. Октября, 71, тел./факс: 8 (347) 235-60-88);
доцент кафедры медицинской генетики и фундаментальной медицины ИДПО.
Список литературы
1. Ba D., Takeichi N., Kodama T., Kobayashi H. Restoration of T cell depression and suppression of blood pressure in spontaneously hypertensive rats (SHR) by thymus grafts or thymus extracts. J. Immunol., 1982, Vol. 128, no. 3, p. 1211.
2. Barhoumi T., Kasal D.A., Li M.W., Shbat L., Laurant P., Neves M.F., Paradis P., Schiffrin E.L. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension, 2011, Vol. 57, no. 3, pp. 469-476.
3. Caillon A., Schiffrin E.L. Role of inflammation and immunity in hypertension: Recent epidemiological, laboratory, and clinical evidence. Curr. Hypertens. Rep., 2016, Vol. 18, no. 3, p. 21.
4. Caillon A., Mian M.O.R., Fraulob-Aquino J.C., Huo K.-G., Barhoumi T., Ouerd S., Sinnaeve P.R., Paradis P., Schiffrin E.L. γδT cells mediate angiotensin II-induced hypertension and vascular injuryclinical perspective. Circulation, 2017, Vol. 135, no. 22, pp. 2155-2162.
5. Carnevale D., Pallante F., Fardella V., Fardella S., Iacobucci R., Federici M., Cifelli G., de Lucia M., Lembo G. The angiogenic factor PLGFmediates a neuroimmune interaction in the spleen to allow the onset of hypertension. Immunity, 2014, Vol. 41, no. 5, pp. 737-752.
6. Ceeraz S., Nowak E.C., Noelle R.J. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol., 2013, Vol. 34, no. 11, pp. 556-563.
7. Chan C.T., Lieu M., Toh B.H., Kyaw T.S., Bobik A., Sobey C.G., Drummond G.R. Antibodies in the pathogenesis of hypertension. Biomed. Res. Int., 2014, Vol. 2014, 504045. doi: 10.1155/2014/504045.
8. Chan C.T., Sobey C.G., Lieu M., Ferens D., Kett M.M., Diep H., Kim H.A., Krishnan S.M., Lewis C.V., Salimova E., Tipping P., Vinh A., Samuel C.S., Peter K., Guzik T.J., Kyaw T.S., Toh B.H., Bobik A., Drummond G.R. Obligatory role for B cells in the development of angiotensin II-dependent hypertension. Hypertension, 2015, Vol. 66, no. 5, pp. 1023-1033.
9. Chen X., Jensen P.E. The role of B lymphocytes as antigen-presenting cells. Arch. Immunol. Ther. Exp. (Warsz.), 2008, Vol. 56, no. 2, p. 77.
10. Dange R.B., Agarwal D., Masson G.S., Vila J., Wilson B., Nair A., Francis J. Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin II-induced hypertension. Cardiovasc. Res., 2014, Vol. 103, no. 1, pp. 17-27.
11. Davey Smith G., Lawlor D.A., Harbord R., Timpson N., Rumley A., Lowe G.D., Day I.N., Ebrahim S. Association of C-reactive protein with blood pressure and hypertension: Life course confounding and mendelian randomization tests of causality. Arterioscler. Thromb. Vasc. Biol., 2005, Vol. 25, no. 5, pp. 1051-1056.
12. de Batista P.R., Palacios R., Martin A., Hernanz R., Medici C.T., Silva M.A., Rossi E.M., Aguado A., Vassallo D.V., Salaices M., Alonso M.J. Toll-like receptor 4 upregulation by angiotensin II contributes to hypertension and vascular dysfunction through reactive oxygen species production. PLoS ONE, 2014, Vol. 9, no. 8, e104020. doi: 10.1371/journal.pone.0104020.
13. Eid R.E., Rao D.A., Zhou J., Lo S.F., Ranjbaran H., Gallo A., Sokol S.I., Pfau S., Pober J.S., Tellides G. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation, 2009, Vol. 119, no. 10, pp. 1424-1432.
14. Espeli M., Smith K.G., Clatworthy M.R. FcγRIIB and autoimmunity. Immunol. Rev., 2016, Vol. 269, no. 1, pp. 194-211.
15. Fauchais A.-L., Lalloué F., Lise M.-C., Boumediene A., Preud’homme J.-L., Vidal E., Jauberteau M.-O. Role of endogenous brain-derived neurotrophic factor and sortilin in B cell survival. J. Immunol., 2008, Vol. 181, no. 5, pp. 3027-3038.
16. Fehervari Z. Isoketals drive hypertension. Nat. Immunol., 2014, Vol. 15, no. 11, p. 1008.
17. Feroze U., Kalantar-Zadeh K., Sterling K.A., Molnar M.Z., Noori N., Benner D., Shah V., Dwivedi R., Becker K., Kovesdy C.P. Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J. Ren. Nutr., 2012, Vol. 22, no. 3, pp. 317-326.
18. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol., 2009, Vol. 9, no. 3, pp. 162-174.
19. Gaffen S.L., Jain R., Garg A.V., Cua D.J. IL-23-IL-17 immune axis: Discovery, mechanistic understanding, and clinical testing. Nat. Rev. Immunol., 2014, Vol. 14, no. 9, pp. 585-600.
20. Guzik T.J., Hoch N.E., Brown K.A., McCann L.A., Rahman A., Dikalov S., Goronzy J., Weyand C., Harrison D.G. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med., 2007, Vol. 204, no. 10, pp. 2449-2460.
21. Harrison D.G., Guzik T.J., Lob H.E., Madhur M.S., Marvar P.J., Thabet S.R., Vinh A., Weyand C.M. Inflammation, immunity, and hypertension. Hypertension, 2011, Vol. 57, no. 2, p. 132.
22. Hoffman W., Lakkis F.G., Chalasani G. B cells, antibodies, and more. Clin. J. Am. Soc. Nephrol., 2016, Vol. 11, no. 1, pp. 137-154.
23. Jose P.A., Raj D. Gut microbiota in hypertension. Curr. Opin. Nephrol. Hypertens., 2015, Vol. 24, no. 5, pp. 403-409.
24. Kamat N.V., Thabet S.R., Xiao L., Saleh M.A., Kirabo A., Madhur M.S., Delpire E., Harrison D.G., McDonough A.A. Renal transporter activation during angiotensin-II hypertension is blunted in interferon-gamma-/-and interleukin-17A -/-mice. Hypertension, 2015, Vol. 65, no. 3, pp. 569-576.
25. Khalesi S., Sun J., Buys N., Jayasinghe R. Effect of probiotics on blood pressure: A systematic review and meta-analysis of randomized, controlled trials. Hypertension, 2014, Vol. 64, no. 4, pp. 897-903.
26. Kobori H., Nangaku M., Navar L.G., Nishiyama A. The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev., 2007, Vol. 59, no. 3, pp. 251-287.
27. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu. Rev. Immunol., 2009, Vol. 27, no. 1, pp. 485-517.
28. Krebs C.F., Lange S., Niemann G., Rosendahl A., Lehners A., Meyer-Schwesinger C., Stahl R.A., Benndorf R.A., Velden J., Paust H.J., Panzer U., Ehmke H., Wenzel U.O. Deficiency of the interleukin 17/23 axis accelerates renal injury in mice with deoxycorticosterone acetate+angiotensin II-induced hypertension. Hypertension, 2014, Vol. 63, no. 3, pp. 565-571.
29. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med., 2005, Vol. 201, no. 2, pp. 233-240.
30. Laurent S., Katsahian S., Fassot C., Tropeano A.-I., Gautier I., Laloux B., Boutouyrie P. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke, 2003, Vol. 34, no. 5, pp. 1203-1206.
31. Li W., Li Z., Chen Y., Li S., Lv Y., Zhou W., Liao M., Zhu F., Zhou Z., Cheng X., Zeng Q., Liao Y., Wei Y. Autoantibodies targeting AT1 receptor from patients with acute coronary syndrome upregulate proinflammatory cytokines expression in endothelial cells involving NF-κB pathway. J. Immunol. Res., 2014, Vol. 2014, 342693. doi: 10.1155/2014/342693.
32. Liao Y.-H., Wei Y.-M., Wang M., Wang Z.-H., Yuan H.-T., Cheng L.-X. Autoantibodies against AT1-receptor and alpha-1-adrenergic receptor in patients with hypertension. Hypertens. Res., 2002, Vol. 25, no. 4, pp. 641-646.
33. Liu A.C., Lee M., McManus B.M., Choy J.C. Induction of endothelial nitric oxide synthase expression by IL- 17 in human vascular endothelial cells: Implications for vascular remodeling in transplant vasculopathy. J. Immunol., 2012, Vol. 188, no. 3, pp. 1544-1550.
34. Liu X., Zhang Q., Wu H., Du H., Liu L., Shi H., Wang C., Xia Y., Guo X., Li C., Bao X., Su Q., Sun S., Wang X., Zhou M., Jia Q., Zhao H., Song K., Niu K. Blood neutrophil to lymphocyte ratio as a predictor of hypertension. Am. J. Hypertens., 2015, Vol. 28, no. 11, pp. 1339-1346.
35. Lord S.J., Rajotte R.V., Korbutt G.S., Bleackley R.C. Granzyme b: A natural born killer. Immunol. Rev., 2003, Vol. 193, no. 1, pp. 31-38.
36. Madhur M.S., Lob H.E., McCann L.A., Iwakura Y., Blinder Y., Guzik T.J., Harrison D.G. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension, 2010, Vol. 55, no. 2, pp. 500-507.
37. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Böhm M., Christiaens T., Cifkova R., de Backer G., Dominiczak A., Galderisi M., Grobbee D.E., Jaarsma T., Kirchhof P., Kjeldsen S.E., Laurent S., Manolis A.J., Nilsson P.M., Ruilope L.M., Schmieder R.E., Sirnes P.A., Sleight P., Viigimaa M., Waeber B., Zannad F., Council E.S.H.S., Redon J., Dominiczak A., Narkiewicz K., Nilsson P.M., Burnier M., Viigimaa M., Ambrosioni E., Caufield M., Coca A., Olsen M.H., Schmieder R.E., Tsioufis C., van de Borne P., Guidelines E.S.C.C.f.P., Zamorano J.L., Achenbach S., Baumgartner H., Bax J.J., Bueno H., Dean V., Deaton C., Erol C., Fagard R., Ferrari R., Hasdai D., Hoes A.W., Kirchhof P., Knuuti J., Kolh P., Lancellotti P., Linhart A., Nihoyannopoulos P., Piepoli M.F., Ponikowski P., Sirnes P.A., Tamargo J.L., Tendera M., Torbicki A., Wijns W., Windecker S., Document R., Clement D.L., Coca A., Gillebert T.C., Tendera M., Rosei E.A., Ambrosioni E., Anker S.D., Bauersachs J., Hitij J.B., Caulfield M., de Buyzere M., de Geest S., Derumeaux G.A., Erdine S., Farsang C., Funck-Brentano C., Gerc V., Germano G., Gielen S., Haller H., Hoes A.W., Jordan J., Kahan T., Komajda M., Lovic D., Mahrholdt H., Olsen M.H., Ostergren J., Parati G., Perk J., Polonia J., Popescu B.A., Reiner Ž., Rydén L., Sirenko Y., Stanton A., Struijker-Boudier H., Tsioufis C., van de Borne P., Vlachopoulos C., Volpe M., Wood D.A. 2013 ESH/ESC guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J., 2013, Vol. 34, no. 28, pp. 2159-2219.
38. Marko L., Kvakan H., Park J.K., Qadri F., Spallek B., Binger K.J., Bowman E.P., Kleinewietfeld M., Fokuhl V., Dechend R., Muller D.N. Interferon-gamma signaling inhibition ameliorates angiotensin II-induced cardiac damage. Hypertension, 2012, Vol. 60, no. 6, pp. 1430-1436.
39. Matsuura E., Atzeni F., Sarzi-Puttini P., Turiel M., Lopez L.R., Nurmohamed M.T. Is atherosclerosis an autoimmune disease? BMC Med., 2014, Vol. 12, p. 47.
40. McHeyzer-Williams L.J., McHeyzer-Williams M.G. Antigen-specific memory Bcell development. Annu. Rev. Immunol., 2005, Vol. 23, pp. 487-513.
41. Mian M.O., Barhoumi T., Briet M., Paradis P., Schiffrin E.L. Deficiency of t-regulatory cells exaggerates angiotensin II-induced microvascular injury by enhancing immune responses. J. Hypertens., 2016, Vol. 34, no. 1, pp. 97-108.
42. Mills C.D. Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: A life or death issue. Crit. Rev. Immunol., 2001, Vol. 21, no. 5, pp. 399-425.
43. Moir S., Ho J., Malaspina A., Wang W., DiPoto A.C., O’Shea M.A., Roby G., Kottilil S., Arthos J., Proschan M.A., Chun T.-W., Fauci A.S. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J. Exp. Med., 2008, Vol. 205, no. 8, pp. 1797-1805.
44. Montezano A.C., Dulak-Lis M., Tsiropoulou S., Harvey A., Briones A.M., Touyz R.M. Oxidative stress and human hypertension: Vascular mechanisms, biomarkers, and novel therapies. Can. J. Cardiol., 2015, Vol. 31, no. 5, pp. 631-641.
45. Murray P.J., Allen J.E., Biswas S.K., Fisher E.A., Gilroy D.W., Goerdt S., Gordon S., Hamilton J.A., Ivashkiv L.B., Lawrence T., Locati M., Mantovani A., Martinez F.O., Mege J.L., Mosser D.M., Natoli G., Saeij J.P., Schultze J.L., Shirey K.A., Sica A., Suttles J., Udalova I., van Ginderachter J.A., Vogel S.N., Wynn T.A. Macrophage activation and polarization: Nomenclature and experimental guidelines. Immunity, 2014, Vol. 41, no. 1, pp. 14-20.
46. Nguyen H., Chiasson V.L., Chatterjee P., Kopriva S.E., Young K.J., Mitchell B.M. Interleukin-17 causes Rhokinase-mediated endothelial dysfunction and hypertension. Cardiovasc. Res., 2013, Vol. 97, no. 4, pp. 696-704.
47. Norlander A.E., Saleh M.A., Pandey A.K., Itani H.A., Wu J., Xiao L., Kang J., Dale B.L., Goleva S.B., Laroumanie F., Du L., Harrison D.G., Madhur M.S. A salt-sensing kinase in T lymphocytes, SGK1, drives hypertension and hypertensive end-organ damage. JCI Insight, 2017, Vol. 2, no. 13, e92801. doi:10.1172/jci.insight.92801.
48. Norlander A.E., Madhur M.S., Harrison D.G. The immunology of hypertension. J. Exp. Med., 2018, Vol. 215, no. 1, p. 21.
49. Norman R.A., Jr., Dzielak D.J., Bost K.L., Khraibi A.A., Galloway P.G. Immune system dysfunction contributes to the aetiology of spontaneous hypertension. J. Hypertens., 1985, Vol. 3, no. 3, pp. 261-268.
50. O’Shea J.J., Paul W.E. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science, 2010, Vol. 327, no. 5969, pp. 1098-1102.
51. Okuda T., Grollman A. Passive transfer of autoimmune induced hypertension in the rat by lymph node cells. Tex. Rep. Biol. Med., 1967, Vol. 25, no. 2, pp. 257-264.
52. Olsen F. Inflammatory cellular reaction in hypertensive vascular disease in man. Acta Pathol. Microbiol. Scand. A, 1972, Vol. 80, no. 2, pp. 253-256.
53. Park M.-J., Lee S.-H., Kim E.-K., Lee E.-J., Baek J.-A., Park S.-H., Kwok S.-K., Cho M.-L. Interleukin-10 produced by myeloid-derived suppressor cells is critical for the induction of tregs and attenuation of rheumatoid inflammation in mice. Sci. Rep., 2018, Vol. 8, no. 1, p. 3753.
54. Pluznick J. A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes, 2014, Vol. 5, no. 2, pp. 202-207.
55. Pons H., Ferrebuz A., Quiroz Y., Romero-Vasquez F., Parra G., Johnson R.J., Rodriguez-Iturbe B. Immune reactivity to heat shock protein 70 expressed in the kidney is cause of salt-sensitive hypertension. Am. J. Physiol. Renal Physiol., 2012, Vol. 304, no. 3, pp. F289-F299.
56. Pushpakumar S., Ren L., Kundu S., Gamon A., Tyagi S.C., Sen U. Toll-like receptor 4 deficiency reduces oxidative stress and macrophage mediated inflammation in hypertensive kidney. Sci. Rep., 2017, Vol. 7, no. 1, p. 6349.
57. Qin J., Li R., Raes J., Arumugam M., Burgdorf K.S., Manichanh C., Nielsen T., Pons N., Levenez F., Yamada T., Mende D.R., Li J., Xu J., Li S., Li D., Cao J., Wang B., Liang H., Zheng H., Xie Y., Tap J., Lepage P., Bertalan M., Batto J.M., Hansen T., le Paslier D., Linneberg A., Nielsen H.B., Pelletier E., Renault P., SicheritzPonten T., Turner K., Zhu H., Yu C., Li S., Jian M., Zhou Y., Li Y., Zhang X., Li S., Qin N., Yang H., Wang J., Brunak S., Dore J., Guarner F., Kristiansen K., Pedersen O., Parkhill J., Weissenbach J., Bork P., Ehrlich S.D., Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature, 2010, Vol. 464, no. 7285, pp. 59-65.
58. Ramezani A., Raj D.S. The gut microbiome, kidney disease, and targeted interventions. J. Am. Soc. Nephrol., 2014, Vol. 25, no. 4, pp. 657-670.
59. Ravandi A., Boekholdt S.M., Mallat Z., Talmud P.J., Kastelein J.J., Wareham N.J., Miller E.R., Benessiano J., Tedgui A., Witztum J.L., Khaw K.T., Tsimikas S. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: Results from the EPICNorfolk Study. J. Lipid Res., 2011, Vol. 52, no. 10, pp. 1829-1836.
60. Rodriguez-Iturbe B., Pons H., Johnson R.J. Role of the immune system in hypertension. Physiol. Rev., 2017, Vol. 97, no. 3, pp. 1127-1164.
61. Rosskopf D., Hartung K., Hense J., Siffert W. Enhanced immunoglobulin formation of immortalized B cells from hypertensive patients. Hypertension, 1995, Vol. 26, no. 3, pp. 432-435.
62. Sakaue T., Suzuki J., Hamaguchi M., Suehiro C., Tanino A., Nagao T., Uetani T., Aono J., Nakaoka H., Kurata M., Sakaue T., Okura T., Yasugi T., Izutani H., Higaki J., Ikeda S. Perivascular adipose tissue angiotensin II type 1 receptor promotes vascular inflammation and aneurysm formation. Hypertension, 2017, Vol. 70, no. 4, pp. 780-789.
63. Saleh M.A., McMaster W.G., Wu J., Norlander A.E., Funt S.A., Thabet S.R., Kirabo A., Xiao L., Chen W., Itani H.A., Michell D., Huan T., Zhang Y., Takaki S., Titze J., Levy D., Harrison D.G., Madhur M.S. Lymphocyte adaptor protein LNK deficiency exacerbates hypertension and end-organ inflammation. J. Clin. Invest., 2015, Vol. 125, no. 3, pp. 1189-1202.
64. Sallusto F., Lenig D., Förster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.Nature, 1999, Vol. 401, no. 6754, p. 708.
65. Schiffrin E.L. Vascular remodeling in hypertension: Mechanisms and treatment. Hypertension, 2012, Vol. 59, no. 2, pp. 367-374.
66. Selvaraj U.M., Poinsatte K., Torres V., Ortega S.B., Stowe A.M. Heterogeneity of B cell functions in strokerelated risk, prevention, injury, and repair. Neurotherapeutics, 2016, Vol. 13, no. 4, pp. 729-747.
67. Seppo L., Jauhiainen T., Poussa T., Korpela R. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am. J. Clin. Nutr., 2003, Vol. 77, no. 2, pp. 326-330.
68. Shah K.H., Shi P., Giani J.F., Janjulia T., Bernstein E.A., Li Y., Zhao T., Harrison D.G., Bernstein K.E., Shen X.Z. Myeloid suppressor cells accumulate and regulate blood pressure in hypertension. Circ. Res., 2015, Vol. 117, no. 10, pp. 858-869.
69. Shi K., Wang F., Jiang H., Liu H., Wei M., Wang Z., Xie L. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig. Dis. Sci., 2014, Vol. 59, no. 9, pp. 2109-2117.
70. Shi Y., Evans J.E., Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature, 2003, Vol. 425, no. 6957, pp. 516-521.
71. Shortman K., Liu Y.J. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol., 2002, Vol. 2, no. 3, pp. 151-161.
72. Sinnaeve P.R., Donahue M.P., Grass P., Seo D., Vonderscher J., Chibout S.D., Kraus W.E., Sketch M., Jr., Nelson C., Ginsburg G.S., Goldschmidt-Clermont P.J., Granger C.B. Gene expression patterns in peripheral blood correlate with the extent of coronary artery disease.PLoS ONE, 2009, Vol. 4, no. 9, e7037. doi: 10.1371/journal.pone.0007037.
73. Sun X.-N., Li C., Liu Y., Du L.-J., Zeng M.-R., Zheng X.-J., Zhang W.-C., Liu Y., Zhu M., Kong D., Zhou L., Lu L., Shen Z.-X., Yi Y., Du L., Qin M., Liu X., Hua Z., Sun S., Yin H., Zhou B., Yu Y., Zhang Z., Duan S.-Z. T-cell mineralocorticoid receptor controls blood pressure by regulating interferon-gammanovelty and significance. Circ. Res., 2017, Vol. 120, no. 10, pp. 1584-1597.
74. Svendsen U.G. The role of thymus for the development and prognosis of hypertension and hypertensive vascular disease in mice following renal infarction. Acta Pathol. Microbiol. Scand. A, 1976, Vol. 84, no. 3, pp. 235-243.
75. Taguchi A., Sanada M., Suei Y., Ohtsuka M., Lee K., Tanimoto K., Tsuda M., Ohama K., Yoshizumi M., Higashi Y. Tooth loss is associated with an increased risk of hypertension in postmenopausal women. Hypertension, 2004, Vol. 43, no. 6, pp. 1297-1300.
76. Tonetti M.S., d’Aiuto F., Nibali L., Donald A., Storry C., Parkar M., Suvan J., Hingorani A.D., Vallance P., Deanfield J. Treatment of periodontitis and endothelial function. N. Engl. J. Med., 2007, Vol. 356, no. 9, pp. 911-920.
77. Vantourout P., Hayday A. Six-of-the-best: Unique contributions of γδT cells to immunology. Nat. Rev. Immunol., 2013, Vol. 13, no. 2, p. 88.
78. Vasan R.S., Beiser A., Seshadri S., Larson M.G., Kannel W.B., d’Agostino R.B., Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA, 2002, Vol. 287, no. 8, pp. 1003-1010.
79. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat. Rev. Immunol., 2008, Vol. 8, no. 7, pp. 523-532.
80. Wang F., Jiang H., Shi K., Ren Y., Zhang P., Cheng S. Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. Nephrology (Carlton), 2012, Vol. 17, no. 8, pp. 733-738.
81. Wang Z., Klipfell E., Bennett B.J., Koeth R., Levison B.S., Dugar B., Feldstein A.E., Britt E.B., Fu X., Chung Y.M., Wu Y., Schauer P., Smith J.D., Allayee H., Tang W.H., DiDonato J.A., Lusis A.J., Hazen S.L. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature, 2011, Vol. 472, no. 7341, pp. 57-63.
82. White F.N., Grollman A. Autoimmune factors associated with infarction of the kidney. Nephron, 1964, Vol. 1, pp. 93-102.
83. Wilck N., Matus M.G., Kearney S.M., Olesen S.W., Forslund K., Bartolomaeus H., Haase S., Mähler A., Balogh A., Markó L., Vvedenskaya O., Kleiner F.H., Tsvetkov D., Klug L., Costea P.I., Sunagawa S., Maier L., Rakova N., Schatz V., Neubert P., Frätzer C., Krannich A., Gollasch M., Grohme D.A., Côrte-Real B.F., Gerlach R.G., Basic M., Typas A., Wu C., Titze J.M., Jantsch J., Boschmann M., Dechend R., Kleinewietfeld M., Kempa S., Bork P., Linker R.A., Alm E.J., Müller D.N. Salt-responsive gut commensal modulates Th17 axis and disease. Nature, 2017, Vol. 551, no. 7682, pp. 585-589.
84. Wu J., Thabet S.R., Kirabo A., Trott D.W., Saleh M.A., Xiao L., Madhur M.S., Chen W., Harrison D.G. Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogenactivated protein kinase. Circ. Res., 2014, Vol. 114, no. 4, pp. 616-625.
85. Wu J., Saleh M.A., Kirabo A., Itani H.A., Montaniel K.R.C., Xiao L., Chen W., Mernaugh R.L., Cai H., Bernstein K.E., Goronzy J.J., Weyand C.M., Curci J.A., Barbaro N.R., Moreno H., Davies S.S., Roberts L.J., II, Madhur M.S., Harrison D.G. Immune activation caused by vascular oxidation promotes fibrosis and hypertension. J. Clin. Invest., 2016, Vol. 126, no. 1, pp. 50-67.
86. Xiao L., Kirabo A., Wu J., Saleh M.A., Zhu L.J., Wang F., Takahashi T., Loperena R., Foss J.D., Mernaugh R.L., Chen W., Roberts J., Osborn J.W., Itani H.A., Harrison D.G. Renal denervation prevents immune cell activation and renal inflammation in angiotensin II-induced hypertension. Circ. Res., 2015, Vol. 117, no. 6, pp. 547-557.
87. Yang T., Santisteban M.M., Rodriguez V., Li E., Ahmari N., Carvajal J.M., Zadeh M., Gong M., Qi Y., Zubcevic J., Sahay B., Pepine C.J., Raizada M.K., Mohamadzadeh M. Gut dysbiosis is linked to hypertension. Hypertension, 2015, Vol. 65, no. 6, pp. 1331-1340.
88. Youn J.C., Yu H.T., Lim B.J., Koh M.J., Lee J., Chang D.Y., Choi Y.S., Lee S.H., Kang S.M., Jang Y., Yoo O.J., Shin E.C., Park S. Immunosenescent CD8 + T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension, 2013, Vol. 62, no. 1, pp. 126-133.
Рецензия
Для цитирования:
Тимашева Я.Р. ИММУНОЛОГИЧЕСКИЕ АСПЕКТЫ ЭССЕНЦИАЛЬНОЙ ГИПЕРТЕНЗИИ. Медицинская иммунология. 2019;21(3):407-418. https://doi.org/10.15789/1563-0625-2019-3-407-418
For citation:
Timasheva Ya.R. IMMUNOLOGICAL ASPECTS OF ESSENTIAL HYPERTENSION. Medical Immunology (Russia). 2019;21(3):407-418. (In Russ.) https://doi.org/10.15789/1563-0625-2019-3-407-418
Просмотров:
1841
Послать статью по эл. почте 